Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients

Blood Cancer J. 2025 Jan 7;15(1):2. doi: 10.1038/s41408-025-01209-9.
No abstract available

Publication types

  • Letter